ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its third quarter 2024 financial results announcement for November 8, 2024, before market open. The company will host a conference call at 8:00 a.m. ET featuring CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call toll-free at 800-445-7795 using Conference ID 4757982. A webcast will be available on the company's website under the Investors section, with a replay accessible for two weeks by calling 800-839-8389.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per l'8 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica alle 8:00 AM ET con il CEO Nikhil Lalwani, il CFO Stephen P. Carey e il Responsabile delle Malattie Rare Chris Mutz. Gli investitori possono accedere alla chiamata gratuitamente al numero 800-445-7795 utilizzando l'ID Conferenza 4757982. Un webcast sarà disponibile sul sito web dell'azienda nella sezione Investitori, con una registrazione accessibile per due settimane chiamando il numero 800-839-8389.
ANI Pharmaceuticals (NASDAQ: ANIP) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 8 de noviembre de 2024, antes de la apertura del mercado. La compañía llevará a cabo una conferencia telefónica a las 8:00 AM ET con el CEO Nikhil Lalwani, el CFO Stephen P. Carey y el Jefe de Enfermedades Raras Chris Mutz. Los inversores pueden acceder a la llamada de forma gratuita al 800-445-7795 utilizando el ID de conferencia 4757982. Una transmisión en vivo estará disponible en el sitio web de la empresa en la sección de Inversores, y una repetición será accesible durante dos semanas llamando al 800-839-8389.
ANI 제약 (NASDAQ: ANIP)은 2024년 3분기 재무 결과 발표를 2024년 11월 8일, 시장 개장 전으로 예정하였습니다. 회사는 CEO 니킬 랄와니(Nikhil Lalwani), CFO 스티븐 P. 캐리(Stephen P. Carey), 희귀 질환 담당 크리스 무츠(Chris Mutz)가 참여하는 전화 회의를 오전 8시 (동부 표준시)에 개최할 예정입니다. 투자자들은 800-445-7795로 무료로 전화를 걸어 회의 ID 4757982를 입력하여 회의에 참여할 수 있습니다. 회사 웹사이트의 투자자 섹션에서 웹캐스트를 제공하며, 녹화는 800-839-8389로 전화하여 2주 동안 접근할 수 있습니다.
ANI Pharmaceuticals (NASDAQ: ANIP) a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le 8 novembre 2024, avant l'ouverture du marché. La société tiendra une conférence téléphonique à 8h00 HE avec le PDG Nikhil Lalwani, le directeur financier Stephen P. Carey et le responsable des maladies rares Chris Mutz. Les investisseurs peuvent accéder à l'appel sans frais au 800-445-7795 en utilisant l'ID de conférence 4757982. Un webinaire sera disponible sur le site de l'entreprise dans la section Investisseurs, avec un replay accessible pendant deux semaines en appelant le 800-839-8389.
ANI Pharmaceuticals (NASDAQ: ANIP) hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für den 8. November 2024, vor Markteröffnung, geplant. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz mit CEO Nikhil Lalwani, CFO Stephen P. Carey und Leiter der Seltenen Erkrankungen Chris Mutz veranstalten. Investoren können kostenlos unter 800-445-7795 anrufen und die Konferenz-ID 4757982 verwenden. Ein Webcast wird auf der Website des Unternehmens im Bereich Investoren verfügbar sein, mit einem Rückblick, der für zwei Wochen über die Nummer 800-839-8389 abgerufen werden kann.
- None.
- None.
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:
| Date | Friday, November 8, 2024 | |
| Time | 8:00 a.m. ET | |
| Toll free (U.S.) | 800-445-7795 | |
| Conference ID | 4757982 | |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section | |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-8389 and entering access code 4757982.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q3 2024 earnings?
What time is ANI Pharmaceuticals (ANIP) Q3 2024 earnings call?
How can I access ANI Pharmaceuticals (ANIP) Q3 2024 earnings call?
How long will ANI Pharmaceuticals (ANIP) Q3 2024 earnings call replay be available?
